Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 24 2024 - 2:00AM
Lift BioSciences Announces Abstract Publications at the American
Society of Clinical Oncology (ASCO) Annual Meeting
Lift BioSciences Announces Abstract
Publications at the American Society of Clinical Oncology (ASCO)
Annual Meeting
London, 24 May 2024 – LIfT
BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech
company about to start clinical trials for its first-in-class
allogeneic innate cell therapy, today announces the publication of
two online abstracts at the annual American Society of Clinical
Oncology, to be held from 31 May to 4 June 2024 in McCormick Place
Convention Centre in Chicago, Illinois, US.
Abstract Publications:
1. Title:
Immuno-Modulatory Alpha Neutrophils: The first-in-class neutrophil
progenitor-based allogeneic immuno-cell therapy with cytotoxic and
immunomodulatory functionality for the treatment of solid
tumoursAuthors: Aoife McGinley, Samuel Florence,
Martin James Woodward, Durva Patel, Andrew Willis, Alex Blyth,
Alfonso Quintas-Cardama, Oxana Polyakova; LIfT Biosciences Ltd.,
London, United Kingdom; LIfT Biosciences, London, United Kingdom;
Foghorn Therapeutics, Cambridge, MAAbstract
number: e14523Session type: Publication
onlySession title: Developmental
Therapeutics—Immunotherapy
2. Title:
Example of a simple and scalable manufacturing process for
Immuno-Modulatory Alpha Neutrophils, a specifically designed
immuno-cell therapy with direct and indirect anti-cancer activity
for solid tumour indicationsAuthors: Durva Patel,
Samuel Florence, Aoife McGinley, Jakub Lich, Urvi Thacker, Alex
Blyth, Andrew Willis, Alfonso Quintas-Cardama, Oxana Polyakova;
LIfT Biosciences Ltd., London, United Kingdom; LIfT Biosciences,
London, United Kingdom; Foghorn Therapeutics, Cambridge,
MAAbstract number: e14512Session
type: Publication onlySession title:
Developmental Therapeutics—Immunotherapy
Full versions of the abstracts are available at:
asco.org/abstracts.
Alex Blyth, Chief Executive Officer of
LIfT BioSciences, commented: “We are pleased to have two
of our abstracts accepted for online publication at this year's
ASCO Annual Meeting, a premier meeting bringing together leaders in
the oncology field. Our abstracts show how our manufacturing
process not only enhances the efficiency and scalability of our
treatments, but also ensures production of the highest quality of
therapeutic cells. Our findings demonstrate the successful
multimodal mechanisms of action of our IMANs and their capability
to immunomodulate the solid tumour microenvironment for
long-lasting tumour control, bringing us one step closer to a
treatment for solid tumours and sustained clinical benefit for
patients. This acceptance signifies the strides our team continue
to make in advancing our IMANs towards the clinic and we are glad
to share this with the scientific community.”
-End-
About LIfT BioSciences
LIfT BioSciences is a biotech bringing to market
a first-in-class alpha neutrophil cell therapy that overcomes the
limitations of current therapies in solid tumours by destroying
tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha
Neutrophils (IMANs) turn the tumour microenvironment against the
tumour as they recruit the rest of the immune system to destroy the
tumour to give a durable response and lasting immunity. The
patented breakthrough N-LIfT platform is produced from a patented
process using exceptional stem cells (iPSC or HSC), a proprietary
enhancement media and genetic engineering (e.g. CARs).
LIfT is working towards expanding LIfT's
immunomodulatory therapy approach into other therapeutical
areas such immunology and inflammation, and antimicrobial
resistance. LIfT is committed to delivering complete remission in
high unmet need solid tumours before the decade is out. LIfT
BioSciences was founded by Alex Blyth following the death of his
mother to pancreatic cancer. See www.liftbiosciences.com.
Further information
|
|
|
Investors & Media: |
|
|
Alex BlythICR ConsiliumMary-Jane Elliott, Namrata Taak, Lindsey
Neville |
+44 (0)7718 759116 |
ablyth@LIfTBioSciences.comliftbiosciences@consilium-comms.com |